Novo Nordisk A/S (NEO:NVON)
Canada
· Delayed Price · Currency is CAD | Market Cap | 234.45B |
| Revenue (ttm) | 66.62B |
| Net Income (ttm) | 22.08B |
| Shares Out | n/a |
| EPS (ttm) | 4.96 |
| PE Ratio | 10.62 |
| Forward PE | 11.85 |
| Dividend | 0.15 (3.79%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 65,199 |
| Average Volume | 99,861 |
| Open | 3.980 |
| Previous Close | 4.030 |
| Day's Range | 3.980 - 4.090 |
| 52-Week Range | 3.780 - 10.370 |
| Beta | 0.40 |
| RSI | 32.95 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to c...
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
Novo Nordisk's Kagrama showed less weight loss than Eli Lilly's Zepbound in a key 84-week trial. The setback could pressure Novo's obesity growth outlook until full data and strategy updates emerge.
GLP-1 drugs protect against new or worsening addictions, large study shows
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. milit...
Looking For A Rebound? China Tech and Emerging Markets Top Oversold List
After a choppy stretch for global equities, a fresh group of widely followed names has slid into deeply oversold territory, potentially setting the stage for sharp snapback moves if risk appetite impr...
Novo Nordisk Gets FDA Warning Over Ozempic Ad
Novo Nordisk Gets FDA Warning Over Ozempic Ad
Novo Nordisk (NVO) Faces FDA Warning Over Ozempic Ad
Novo Nordisk (NVO) Faces FDA Warning Over Ozempic Ad
Novo Nordisk gets another FDA warning over GLP-1 ad claims
Bearish Sentiment Surrounds Novo Nordisk (NVO) Amid Stock Decline
Bearish Sentiment Surrounds Novo Nordisk (NVO) Amid Stock Decline
US FDA warns Novo for second time about misleading Ozempic advertising
The U.S. Food and Drug Administration has told Novo Nordisk to stop running a consumer ad for its blockbuster diabetes drug Ozempic, saying the commercial makes false and misleading claims abou...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised...
Aspen expects Canada nod for generic targeting Novo’s Ozempic by September
Novo Nordisk (NVO) stock is in focus as Aspen Pharmacare expects Canada to approve its generic Ozempic by September. Read more here.
Novo Nordisk Addresses Economic Risks of Obesity on World Obesity Day
Thailand is among the countries worldwide battling non-communicable diseases (NCDs), with various control measures targeting dietary intake and lifestyle modification. However, the prevalence of overw...
Novo Nordisk AS (NVO) Trading Down 4.42% on Mar 3
Novo Nordisk AS (NVO) Trading Down 4.42% on Mar 3
4 Factor Dividend Growth Strategy Remains Ahead Of Its Benchmark
The 4-Factor Dividend Growth Portfolio, a rules-based alternative to SCHD, targets high-quality, growth-oriented dividend stocks using four equally weighted metrics. Since inception, the strategy has ...
Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
Novo Nordisk faces persistent valuation declines amid margin uncertainty, competitive pressures, and negative 2026 growth guidance. Despite margin compression risks, NVO remains a speculative contrari...
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports
Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk , its CEO told Germany's Hand...
Goldman Sachs Downgrades Novo Nordisk (NVO) After CagriSema Results
Goldman Sachs Downgrades Novo Nordisk (NVO) After CagriSema Results
Why I'm Not Worried About Novo Nordisk Stock
Investors have been dumping shares of Novo Nordisk amid concerns it can't keep up with Eli Lilly. Novo Nordisk is expecting sales to decline this year, potentially by double digits.
Novo Nordisk downgraded at Goldman Sachs on disappointing CagriSema data
Novo Nordisk to Invest $506 Million in Ireland for Wegovy Production
Novo Nordisk to Invest $506 Million in Ireland for Wegovy Production
Novo Nordisk to Spend â¬432 Million Expanding Irish Wegovy Production
Novo Nordisk to Spend â¬432 Million Expanding Irish Wegovy Production
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo ex...
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S.
Monday's Market Movers: CRWD Rallies, NVO Downgrade, BRK/B Earnings
As markets grapple with the U.S. and Israel joint attack on Iran, Diane King Hall turns to stock movers kicking off the new trading week. CrowdStrike's (CWRD) upgrade from Piper Sandler signals what t...
Novo Nordisk confirms €432m investment in Athlone plant
Danish drugmaker Novo Nordisk, which is expecting approval for the pill version of its anti-obesity treatment Wegovy in Europe later this year, has confirmed an investment of €432m in its manufacturin...